<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00914654</url>
  </required_header>
  <id_info>
    <org_study_id>FOR2009JE</org_study_id>
    <secondary_id>EudraCT number 2009-012039-14</secondary_id>
    <nct_id>NCT00914654</nct_id>
  </id_info>
  <brief_title>Concentrations of Formoterol in Blood and Urine</brief_title>
  <official_title>Blood and Urinary Concentrations of Inhaled Formoterol in Asthmatic Subjects and Elite Athletes With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hormone Laboratory, Aker University Hospital, Oslo, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the blood and urine concentrations of inhaled
      formoterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the serum and urine concentrations after inhalation of
      18 microgram formoterol as one dose.

      Furthermore to investigate the serum and urine concentrations of inhaled formoterol and
      evaluate the difference between three groups: healthy men, male asthmatic subjects and male
      elite athletes with asthma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum and urine concentrations of formoterol</measure>
    <time_frame>baseline, 4, 8, and 12 hours after medicine administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Healthty</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 healthy men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthmatics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 male asthmatic subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elite asthmatics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 male elite athletes with asthma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inhaled formoterol</intervention_name>
    <description>Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.</description>
    <arm_group_label>Healthty</arm_group_label>
    <arm_group_label>Asthmatics</arm_group_label>
    <arm_group_label>Elite asthmatics</arm_group_label>
    <other_name>Oxis Turbohaler 9 microg/dose, MA no. 30072.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physician-diagnosed asthma with positive reversibility or challenge test.

          -  Informed consent.

          -  Age between 18-45 years.

          -  Sex: male.

          -  Asthma classified as mild to moderate according to GINA guidelines.

          -  Used beta-2-agonist in minimum 12 months.

        Exclusion Criteria:

          -  Smokers or ex-smokers with a smoking history of 10 pack years or more.

          -  Respiratory tract infections within the last 2 weeks prior to study day.

          -  Subjects with other chronic diseases than asthma and allergy.

          -  Allergy towards the study medicine.

          -  Use of beta-2-agonist 10 days prior to study day.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jimmi Elers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Respiratory Research Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jimmi Elers, MD</last_name>
    <phone>+45 35313208</phone>
    <email>jele0004@bbh.regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital, Respiratory Research Unit</name>
      <address>
        <city>Kobenhavn NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>June 4, 2009</last_update_submitted>
  <last_update_submitted_qc>June 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jimmi Elers</name_title>
    <organization>Bispebjerg Hospital, Respiratory Research Unit</organization>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Doping</keyword>
  <keyword>Formoterol</keyword>
  <keyword>Urinary concentrations</keyword>
  <keyword>Beta-agonists</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

